Hematopoietic stem cell (HSC) gene therapy for hemophilia Roctavian and Hemgenix are in-vivo gene therapies where an AAV vector delivers a functional copy of the defective gene to hepatocytes, the physiological producers of Factor VIII and XI respectively. Issues with those therapies has been their durability (the effect appears to wane over time) as well […]
